← Leaderboards
Robert John Vandenberg
Albany College Of Pharmacy
$920,446
Attributed
$1,840,892
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $534.1K · FY2019–22$1M$750K$500K$250K$0
'19
'20
'21
'22
Funding mix
By agency
NIH$1,840,892 · 1
By mechanism
R01$1,840,892 · 1
Top collaborators
- Christopher L. Cioffi4 shared
Others in their field
Other Emerging Leaders on “Disinhibition”
- Meghan E. Sise · Massachusetts General Hospital$2,974,380
- Elizabeth Kathleen Lucas · North Carolina State University Raleigh$2,532,762
- Akhgar Ghassabian · New York University School Of Medicine$2,380,516
- Bo Duan · University Of Michigan At Ann Arbor$2,199,525
- Kyle S. Burger · Univ Of North Carolina Chapel Hill$2,189,095
- Joshua Levitz · Weill Medical Coll Of Cornell Univ$2,140,541
Research focus
DisinhibitionDissociationAcute PainAbsorptionAdverse EffectsAbsence Of Pain SensationAnalogAnimal ModelBaseAdultBehavioral ModelBenchmarkingBindingAnalgesicsBrainCharacteristicsChronic Neuropathic PainChronic PainClinical TrialsCollectionCostCounterscreenDesignDorsal Horn
Grant awards (4)
Discovery and development of novel glycine transporter-2 inhibitors for the treatment of neuropathic pain$455,166
R01 · FY2022 · DA
Discovery and development of novel glycine transporter-2 inhibitors for the treatment of neuropathic pain$430,744
R01 · FY2021 · DA
Discovery and development of novel glycine transporter-2 inhibitors for the treatment of neuropathic pain$420,857
R01 · FY2020 · DA
Discovery and development of novel glycine transporter-2 inhibitors for the treatment of neuropathic pain$534,125
R01 · FY2019 · DA